Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Recruiting · NCT06384560 · Registry updated 2026-02-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) | Borderline Resectable Pancreatic Adenocarcinoma; Localized Pancreatic Adenocarcinoma; Resectable Pancreatic Adenocarcinoma | Recruiting | Phase 1 / Phase 2 | 2026-02-13 | NCT06384560 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Amsterdam UMC, location VUmc | 102 |
| Erasmus Medical Center | 271 |
| Maastricht University Medical Center | 157 |
| St. Antonius Hospital | 45 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Amsterdam University Medical Center | Amsterdam | Netherlands | 35 |
| Erasmus University Medical Center | Rotterdam | Netherlands | 21 |
| Maastricht University Medical Center | Maastricht | Netherlands | 23 |
| St. Antonius Ziekenhuis | Nieuwegein | Netherlands | 25 |